A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Key facts
- Where
- Asheville, Atlanta, Austin, Baltimore, Bellaire, Boston, Bowling Green, Canton, Chattanooga, Clearwater, Dallas, Englewood, Farmington Hills, Flint, Florence, Gulfport, Houston, Huntington Beach, Indianapolis, Jacksonville, Kansas City, Las Vegas, Los Angeles, Macon, Mesquite, Metairie, Miami, Monroe, Nashville, New Orleans, Newark, Ocoee, Omaha, Orange, Orlando, Philadelphia, Phoenix, Port Charlotte, Portland, Pottstown, Rochester, Round Rock, Sacramento, Salt Lake City, San Antonio, San Francisco, Sandy City, Santa Clarita, Shreveport, Stockbridge, Summerville, Torrance, Walnut Creek, Washington D.C., West Palm Beach, and Wilmington, United StatesSee the 64 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06727604, who can take part
Where in United States
- Asheville, North CarolinaHospital not named in the registryTaking people
- Atlanta, GeorgiaHospital not named in the registryTaking people
- Austin, TexasHospital not named in the registryTaking people
- Baltimore, MarylandHospital not named in the registryTaking people
- Bellaire, TexasHospital not named in the registryTaking people
- Boston, MassachusettsHospital not named in the registryTaking people
- Bowling Green, KentuckyHospital not named in the registryTaking people
- Canton, OhioHospital not named in the registryTaking people
- Chattanooga, TennesseeHospital not named in the registryTaking people
- Clearwater, FloridaHospital not named in the registryTaking people
- Dallas, TexasHospital not named in the registryTaking people
- Dallas, TexasHospital not named in the registryNo longer taking part
- Englewood, ColoradoHospital not named in the registryTaking people
- Farmington Hills, MichiganHospital not named in the registryTaking people
- Flint, MichiganHospital not named in the registryTaking people
- Florence, KentuckyHospital not named in the registryTaking people
- Gulfport, MississippiHospital not named in the registryTaking people
- Houston, TexasHospital not named in the registryTaking people
- Houston, TexasHospital not named in the registryNo longer taking part
- Huntington Beach, CaliforniaHospital not named in the registryTaking people
- Indianapolis, IndianaHospital not named in the registryTaking people
- Jacksonville, FloridaHospital not named in the registryTaking people
- Jacksonville, FloridaHospital not named in the registryTaking people
- Kansas City, KansasHospital not named in the registryTaking people
- Las Vegas, NevadaHospital not named in the registryTaking people
- Los Angeles, CaliforniaHospital not named in the registryTaking people
- Los Angeles, CaliforniaHospital not named in the registryTaking people
- Macon, GeorgiaHospital not named in the registryTaking people
- Mesquite, TexasHospital not named in the registryTaking people
- Metairie, LouisianaHospital not named in the registryTaking people
- Miami, FloridaHospital not named in the registryTaking people
- Miami, FloridaHospital not named in the registryTaking people
- Monroe, New YorkHospital not named in the registryTaking people
- Nashville, TennesseeHospital not named in the registryTaking people
- Nashville, TennesseeHospital not named in the registryTaking people
- New Orleans, LouisianaHospital not named in the registryTaking people
- Newark, DelawareHospital not named in the registryTaking people
- Ocoee, FloridaHospital not named in the registryTaking people
- Omaha, NebraskaHospital not named in the registryTaking people
- Orange, CaliforniaHospital not named in the registryTaking people
- Orlando, FloridaHospital not named in the registryNo longer taking part
- Philadelphia, PennsylvaniaHospital not named in the registryNo longer taking part
- Phoenix, ArizonaHospital not named in the registryTaking people
- Phoenix, ArizonaHospital not named in the registryNo longer taking part
- Port Charlotte, FloridaHospital not named in the registryTaking people
- Portland, OregonHospital not named in the registryTaking people
- Pottstown, PennsylvaniaHospital not named in the registryTaking people
- Rochester, MinnesotaHospital not named in the registryTaking people
- Round Rock, TexasHospital not named in the registryTaking people
- Sacramento, CaliforniaHospital not named in the registryTaking people
- Salt Lake City, UtahHospital not named in the registryTaking people
- San Antonio, TexasHospital not named in the registryTaking people
- San Antonio, TexasHospital not named in the registryTaking people
- San Francisco, CaliforniaHospital not named in the registryTaking people
- Sandy City, UtahHospital not named in the registryTaking people
- Santa Clarita, CaliforniaHospital not named in the registryNo longer taking part
- Shreveport, LouisianaHospital not named in the registryTaking people
- Stockbridge, GeorgiaHospital not named in the registryNo longer taking part
- Summerville, South CarolinaHospital not named in the registryTaking people
- Torrance, CaliforniaHospital not named in the registryTaking people
- Walnut Creek, CaliforniaHospital not named in the registryNo longer taking part
- Washington D.C., District of ColumbiaHospital not named in the registryTaking people
- West Palm Beach, FloridaHospital not named in the registryNo longer taking part
- Wilmington, North CarolinaHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Immunovant Sciences GmbH
- Trial code
- NCT06727604EU 2024-516020-33-00
- Record updated
- 25 August 2026
- Original description
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Inclusion: Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures; Male or female participants aged ≥ 18 years; Participants with diagnosis of GD who are hyperthyroid despite ATD treatment; Other, more specific inclusion criteria are defined in the protocol.
Exclusion: Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy; Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk; Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation; Additional exclusion criteria are defined in the protocol.